Analyst Dylan Van Haaften of Stifel Nicolaus maintained a Buy rating on Medartis Holding AG (MED – Research Report), retaining the price target of CHF86.00.
Dylan Van Haaften has given his Buy rating due to a combination of factors that indicate a positive outlook for Medartis Holding AG. The company has shown significant changes under the leadership of its new CEO, Matthias Schupp, with a focus on addressing investor concerns such as the direct/indirect sales mix and working capital issues. These changes are expected to improve the company’s operational efficiency and market adaptability.
Additionally, Medartis is concentrating on its Upper Extremities portfolio, which has shown promising growth potential in the U.S. market. The acquisition of NeoOrtho is another strategic move, providing Medartis with a broader product range and access to larger markets, particularly in Latin America. Furthermore, the company’s guidance for FY25 indicates strong organic sales growth and improved EBITDA margins, suggesting a robust financial performance in the coming years. These strategic initiatives and financial projections underpin Van Haaften’s optimistic Buy rating for Medartis Holding AG.
According to TipRanks, Van Haaften is ranked #7686 out of 9386 analysts.